October 17,Hansoh PharmaAndAskGene Pharmarespectively announced that their products have completed an overseas licensing deal; in addition,V立志博AndPuregon BioAlso signed a licensing collaboration on the evening of October 16.On October 17, Hansoh Pharma announced that it had entered intoRocheSign the License Agreement for HS-20110.Hansoh Pharma Grants Roche Globally(Excluding Mainland China, Hong Kong, Macao, and Taiwan)Exclusive rights to advance the development and commercialization of HS-20110.Screenshot source: Official WeChat account of the companyAccording to the agreement, Hansoh Pharma will obtain$80 millionThe down payment, and is eligible to receive milestone payments based on the product's development, registration approval, and commercialization progress, as well as tiered royalties from potential future product sales.
HS-20110 is a novelPotential First-in-ClassAntibody-Drug Conjugates（ADC）, composed of CDH17 monoclonal antibody and topoisomerase inhibitor（TOPOi）The payload is linked through covalent bonds. This therapy has demonstrated broad application potential in the field of solid tumors and is currently being developed in China and the United States for the treatment of colorectal cancer and other solid tumors.Global Phase IClinical trial.Notably, this is not the first time Hansoh has collaborated with an MNC, having previously partnered withRegeneron, Merck, GSKHas reached a licensing agreement.Screenshot source: Insight databaseOn October 17, AskGene PharmaHansoh Pharmaceutical Group Company Limited's subsidiary AskGene Pharma Inc. and Visara, Inc.Class 1 Innovative Drug ASKG712Reach an authorized licensing agreement,The licensed territory is Greater China.(Including mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and the Taiwan region of China), Singapore, Thailand, Malaysia, Indonesia, Vietnam, South Korea, and India, Visara will obtain exclusive rights for the development, production, and commercialization of the ASKG712 project within the licensed territory.Source of screenshot: Corporate announcementWithin 30 working days after the agreement takes effect, Visara will pay AskGene Pharma$70 millionA one-time, non-refundable, and non-deductible upfront payment.AskGene Pharma is entitled to receive milestone payments related to research and development, registration, and commercialization, with a maximum cap of$89 million. In addition,AskGene Pharma has the right to collect a certain percentage of royalties based on the annual net sales of the product in the licensed region.At the same time, the announcement pointed out that,This agreement shall become effective as of the date when I-Mab completes the capital increase of Visara. After this agreement becomes effective, it shall remain in effect unless terminated early according to the terms stipulated in the agreement.ASKG712 is a Class 1 innovative drug independently developed by AskGene Pharma, with independent intellectual property rights.Can simultaneously target VEGF and ANG-2. While blocking the VEGF/VEGFR signaling pathway and controlling the formation of new blood vessels, it can effectively inhibit ANG-2 signaling to improve vascular stability and reduce retinal inflammation. It is clinically used for treating macular diseases of the fundus and is currently inPhase IIa Clinical Study in China。Phase I dose escalation and dose expansion results showed that ASKG712 has good safety and efficacy. Meanwhile, preclinical data indicate that, compared to existing treatments, ASKG712 exhibits stronger binding activity to VEGF and ANG-2, with promising potential.Enhance efficacy while extending the dosing interval, reduce frequent intravitreal injections, and improve patient compliance.October 16,V立志博与 Dianthus Therapeutics Announce Exclusive Global Partnership to Advance Novel Anti-BDCA2/TACI Bispecific Fusion Protein LBL-047(Developed by Dianthus Therapeutics as DNTH212 outside Greater China)。Screenshot source: Official WeChat account of the companyAccording to the terms of the agreement, Viva Biotech will grant Dianthus exclusive rights to research, develop, manufacture, and commercialize LBL-047 outside of Greater China, obtaining the highest$38 millionThe upfront payment and near-term milestone payments, including a $20 million upfront payment, a $5 million payment in the fourth quarter of 2025, and up to $13 million in potential near-term milestone payments.The Total Amount of the Transaction(Including clinical development, regulatory and commercial milestones)Up to 1 billion US dollarsIn addition, V立志博 is entitled to receive tiered royalties on net sales outside the Greater China region, with rates ranging from mid-single digits to low double digits.LBL-047 is a product of Weili Zhibo.Preclinical Pipeline, as aFirst-in-class, long-acting bispecific fusion protein, which is designed to selectively deplete plasmacytoid dendritic cells（pDCs）To reduce Type I interferon（IFN-I）Generation, while inhibiting the BAFF/APRIL signaling pathway to block B-cell activation, survival, and antibody production. By targeting two key drivers in the pathogenesis of autoimmune diseases, this differentiated strategyExpected to cover multiple autoimmune indications, maximizing its clinical value and commercial potential.Screenshot source: Official WeChat account of the companyCurrently, LBL-047 has been approved for clinical trials in the United States.（IND）Approval and acceptance of China IND. Purigen BioNext-Generation In Situ Editing TherapyOctober 16,PRIGEN Collaborates with Gilead Subsidiary KITE PHARMA, INC. and Signs Licensing and Collaboration AgreementThe cooperation region is global.. This global collaboration aims to support and accelerateNext-Generation In Situ Editing TherapyResearch and development, committed to optimizing the entire process from early discovery to clinical development, in order to bring innovative therapies with potentially life-changing significance to patients more efficiently.Source of screenshot: Corporate announcementAccording to the agreement, PuriJin has the right and has received a total of$1.20 billionThe down payment, moreover, after achieving specific milestones, Puruijin is entitled to receive a total amount of up to$1.52 billionMilestone cash payments and sales royalties based on future net product sales.Currently, the two companies have not disclosed their respective target indications.Notably, in vivo CAR-T has become one of the competitive fields that MNCs are entering.In June this year, AbbVie acquired Capstan for $2.1 billion, gaining access to in vivo CAR-T therapies and targeted lipid nanoparticles applicable to autoimmune diseases.（tLNP）Platform income in hand;On October 10, BMS announced that it would acquire Orbital for $1.5 billion in cash.The core asset of the acquisition is the autologous CAR-T cell therapy OTX-201.
